|
Sign In to gain access to subscriptions and/or personal tools.
|
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis
H M Bastian
487 Boshell Diabetes Building, 1808 7th Avenue South, The University of Alabama at Birmingham, Birmingham, AL, 35294, USA. Holly.bastian{at}ccc.uab.edu
J M Roseman
Department of Epidemiology, University of Alabama at Birmingham, Alabama, USA
G Mcgwin, Jr
Department of Surgery, Section of Trauma, Burns and Critical Care, Schools of Medicine and Public Health, University of Alabama at Birmingham, Alabama, USA
G S Alarcón
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Alabama, USA
A W Friedman
Department of Medicine, Division of Rheumatology and Clinical Immunogenetics, The University of Texas–Houston Health Science Center, Houston, Texas, USA
B J Fessler
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Alabama, USA
B A Baethge
Department of Medicine, Division of Rheumatology, The University of Texas Medical Branch, Galveston, Texas, USA
J D Reveille
Department of Medicine, Division of Rheumatology and Clinical Immunogenetics, The University of Texas–Houston Health Science Center, Houston, Texas, USA
Lumina Study Group
The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de" ned by the American College of Rheumatology (ACR) criteria (65 Hispanics, 93 African-Americans and 91 Caucasians). First, we determined the cumulative incidence of LN in all patients. Next, we determined the predictors for LN in those with nephritis occurring after diagnosis. The dependent variable, LN, was de" ned by: (1) A renal biopsy demonstrating World Health Organization (WHO), class II–V histopathology; and/or (2) proteinuria 0.5 g=24 h or 3 + proteinuria attributable to SLE; and/or (3) one of the following features also attributable to SLE and present on two or more visits, which were performed at least 6 months apart— proteinuria 2 +, serum creatinine 1.4 mg/dl, creatinine clearance  79 ml/min, 10 RBCs or WBCs per high power " eld (hpf), o 3 granular or cellular casts per hpf. Independent variables assessed at diagnosis, and if absent, at baseline, were from four domains: sociodemographic, clinical, immunologic and immunogenetic (including the complete antibody pro" le and MHC class II alleles), and health habits. Variables with P < 0.05 by chi square analyses were entered into domain-speci"c stepwise logistic regression analyses controlling for disease duration, with LN as the dependent variable. Signi" cant domain-speci"c regression variables (P 0.1) were then entered into an overall model. The cumulative incidence of LN was 54.3% in all patients, and 35.3% for those developing LN after diagnosis. LN after diagnosis occurred in 43.1% of 65 Hispanics, 50.5% of 93 African-Americans, and 14.3% of 91 Caucasians, P < 0.0001. The duration of follow-up for those with LN after diagnosis was 5.5 2.4 vs 4.0 2.9 years for those without LN. Hispanic (odds ratio (OR) = 2.71, 95% con" dence limits (CL) = 1.07–6.87, P < 0.04) and African-American ethnicities (OR = 3.13, 95% CL = 1.21–8.09, P < 0.02), not married or living together (OR = 3.45, 95% CL = 1.69–7.69, P < 0.0003), higher SLAM score (OR = 1.11, 95% CL = 1.02–1.19, P < 0.007), anti-dsDNA (OR = 3.14, 95% CL = 1.50–6.57, P < 0.0001) and anti-RNP (OR = 4.24, CL = 1.98–9.07, P < 0.0001) antibodies were shown to be signi" cant predictors of the occurrence of LN. Repeated analyses excluding the patients with missing HLA data showed that absence of HLA-DQB1*0201 was also a signi" cant predictor for the occurrence of LN (OR = 2.34, CL = 1.13–5.26, P < 0.04).
In conclusion, LN occurred signi" cantly more often in Hispanics and African-Americans with SLE. Sociodemographic,clinical and immunologic/immunogenetic factors seem to be predictive of LN occurring after the diagnosis of SLE has been made.
Key Words: SLE • nephritis • predictors
Lupus, Vol. 11, No. 3,
152-160 (2002)
DOI: 10.1191/0961203302lu158oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. G. Uribe, J. Romero-Diaz, M. Apte, M. Fernandez, P. I. Burgos, J. D. Reveille, J. Sanchez-Guerrero, and G. S. Alarcon
Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico
Rheumatology,
November 1, 2009;
48(11):
1392 - 1397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gonzalez, G. Pons-Estel, J Zhang, L. Vila, J. Reveille, G. Alarcon, and for the LUMINA study group
Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort
Lupus,
August 1, 2009;
18(9):
822 - 830.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow
Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy
J. Am. Soc. Nephrol.,
April 1, 2009;
20(4):
901 - 911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al.
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
Ann Rheum Dis,
April 1, 2009;
68(4):
477 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S Alarcon
Lessons from LUMINA: a multiethnic US cohort
Lupus,
November 1, 2008;
17(11):
971 - 976.
[PDF]
|
|
|
|
|
|
|
A. Sestak, S. Nath, J. Kelly, G. Bruner, J. James, and J. Harley
Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race
Lupus,
November 1, 2008;
17(11):
1004 - 1009.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Chambers, R Raine, A Rahman, K Hagley, K De Ceulaer, and D Isenberg
Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica
Lupus,
August 1, 2008;
17(8):
761 - 769.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. D. Linnik, A. M. O'Rourke, and M. A. Crowther
Pharmacokinetics of High-Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation
J. Clin. Pharmacol.,
August 1, 2008;
48(8):
909 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nazarinia, F Ghaffarpasand, A Shamsdin, A. Karimi, N Abbasi, and A Amiri
Systemic lupus erythematosus in the Fars Province of Iran
Lupus,
March 1, 2008;
17(3):
221 - 227.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Burling, J. Ng, H. Thein, J. Ly, M.R. Marshall, and P. Gow
Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort
Lupus,
October 1, 2007;
16(10):
830 - 837.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Al-Rayes, R. Al-Swailem, M. Arfin, S. Sobki, S. Rizvi, and M. Tariq
Lupus Around the World: Systemic lupus erythematosus and infections: a retrospective study in Saudis
Lupus,
September 1, 2007;
16(9):
755 - 763.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Wadee, M. Tikly, and M. Hopley
Causes and predictors of death in South Africans with systemic lupus erythematosus
Rheumatology,
September 1, 2007;
46(9):
1487 - 1491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Isenberg, J. J. Manson, M. R. Ehrenstein, and A. Rahman
Fifty years of anti-ds DNA antibodies: are we approaching journey's end?
Rheumatology,
July 1, 2007;
46(7):
1052 - 1056.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.M. Bertoli, L.M. Vila, M. Apte, B.J. Fessler, H.M. Bastian, J.D. Reveille, and G.S. Alarcon
Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage
Lupus,
June 1, 2007;
16(6):
410 - 417.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Chaiamnuay, A. M Bertoli, J. M Roseman, G. McGwin, M. Apte, S. Duran, L. M Vila, J. D Reveille, and G. S Alarcon
African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV)
Ann Rheum Dis,
May 1, 2007;
66(5):
618 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Bastian, G. S. Alarcon, J. M. Roseman, G. McGwin Jr, L. M. Vila, B. J. Fessler, J. D. Reveille, and for the LUMINA study group
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria
Rheumatology,
April 1, 2007;
46(4):
683 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C A Hitchon and C A Peschken
Sm antibodies increase risk of death in systemic lupus erythematosus
Lupus,
March 1, 2007;
16(3):
186 - 194.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R T Naismith, K Trinkaus, and A H Cross
Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review
Multiple Sclerosis,
November 1, 2006;
12(6):
775 - 781.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C S Lau, G Yin, and M Y Mok
Ethnic and geographical differences in systemic lupus erythematosus: an overview
Lupus,
November 1, 2006;
15(11):
715 - 719.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Sule and M Petri
Socioeconomic status in systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11):
720 - 723.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Flower, A Hennis, I R Hambleton, and G Nicholson
Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes
Lupus,
October 1, 2006;
15(10):
689 - 694.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G S Alarcon, H M Bastian, T M Beasley, J M Roseman, F K Tan, B J Fessler, L M Vila, G McGwin, J D Reveille, and LUMINA Study Group
Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA): contributions of admixture and socioeconomic status to renal involvement
Lupus,
January 1, 2006;
15(1):
26 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S R. Sprovieri and Y A. Sens
Polymorphisms of the renin-angiotensin system genes in Brazilian patients with lupus nephropathy
Lupus,
May 1, 2005;
14(5):
356 - 362.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Contreras, E Tozman, N. Nahar, and D. Metz
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
Lupus,
March 1, 2005;
14(3_suppl):
s33 - s38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Contreras, E. Tozman, N. Nahar, and D. Metz
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
Lupus,
January 1, 2005;
14(1_suppl):
s33 - s38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Albrecht, J A Berlin, I M Braverman, J P Callen, M I Costner, J Dutz, D Fivenson, A G Franks, J L Jorizzo, L A Lee, et al.
Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus
Lupus,
November 1, 2004;
13(11):
839 - 849.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M A Rabbani, B K Siddiqui, M H Tahir, B Ahmad, A Shamim, S M. Shah, and A Ahmad
Systemic lupus erythematosus in Pakistan
Lupus,
October 1, 2004;
13(10):
820 - 825.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I E A Hoffman, I Peene, L Meheus, T W J Huizinga, L Cebecauer, D Isenberg, K De Bosschere, F Hulstaert, E M Veys, and F De Keyser
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus
Ann Rheum Dis,
September 1, 2004;
63(9):
1155 - 1158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Alba, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D'Cruz, and G R V Hughes
Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis
Ann Rheum Dis,
June 1, 2003;
62(6):
556 - 560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
